In the final days of 2024, three pharmaceutical giants sued the federal government. In their joint lawsuit, Amgen, Eli Lilly ...

Tirzepatide is just as effective in reducing cardiovascular risk driven by central adiposity as that driven by general ...

Shares of Amgen Inc. AMGN advanced 1.24% to $297.93 Thursday, on what proved to be an all-around dismal trading session for ...

Manufacturers of medicines, including Pfizer and Eli Lilly, have spent a combined $450,000 lobbying against price caps on ...

We recently compiled a list of the 10 Cheap Pharmaceutical Stocks to Buy According to Analysts. In this article, we are going to take a look at where Amgen Inc.

Amgen will continue to advance half of the combo, PRMT5 inhibitor AMG 193, for which it is running a mid-stage trial in ...

Amgen's dividend yield remains attractive, with a moderate payout ratio and strong free cash flow. Click here to see why AMGN stock is a Hold.

While Ideaya is letting Amgen go, it is retaining an interest in MAT2A-PRMT5 combinations. Ideaya has a PRMT5 inhibitor, ...

Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various ...

Amgen posted strong earnings beat and has an attractive dividend, and technical chart forecasting positive future performance. Click to read why AMGN is a Buy.